Vitamin D Repletion for Adults with Serum 25‑Hydroxyvitamin D ≈ 21 ng/mL

Classification & Target Levels

Serum 25‑(OH)D of 21 ng/mL falls within the insufficient range (20–29 ng/mL) and warrants repletion therapy to achieve a target > 30 ng/mL. [1][2]4

AACE/ACE 2020 guidelines give a strong recommendation to prescribe 5,000 IU vitamin D₃ (cholecalciferol) daily for 8–12 weeks in adults with serum 25‑(OH)D 20–29 ng/mL (insufficient) or < 20 ng/mL (deficient). [1][2][3][4]5
Vitamin D₃ is preferred over vitamin D₂ because most assays reliably measure 25‑(OH)D₃, and cholecalciferol sustains serum levels longer with intermittent dosing. [1][2][3][4]5

Weekly high‑dose regimen: 50,000 IU vitamin D₂ (ergocalciferol) once weekly for 8 weeks, followed by a repeat 25‑(OH)D measurement. [6][7]8
Low‑dose incremental regimen: Add 1,000 IU vitamin D₃ daily and re‑measure after 3 months; this more conservative approach may require a longer period to reach target levels. [6][7]8

Re‑check serum 25‑(OH)D 8–12 weeks after initiating any repletion protocol to confirm adequate rise and guide further therapy. [1][2]3
Maintenance after target achievement: Continue with 1,000–2,000 IU vitamin D₃ daily to sustain levels > 30 ng/mL. [1][2][3][4]5

Approximate rule of thumb: 1,000 IU vitamin D₃ daily raises 25‑(OH)D by ~10 ng/mL; therefore, 5,000 IU daily is expected to increase levels by roughly 40–50 ng/mL over 8–12 weeks, though individual response varies with baseline level, body habitus, and absorption. 9

Avoid large bolus doses (e.g., 500,000 IU annually or 60,000 IU monthly) because they have been linked to increased falls and fractures in older adults, likely due to excess 24‑hydroxylation producing inactive metabolites. [1][2][3][4]
Higher daily doses may be needed in individuals with obesity, malabsorption syndromes, or those taking medications that accelerate vitamin D catabolism (e.g., anticonvulsants, glucocorticoids). [1][2][3][5]
Daily dosing is preferred over weekly or monthly bolus regimens to mimic physiologic cutaneous synthesis and minimize metabolic disturbances. [1][2]3
Monitor for hypercalcemia in patients with granulomatous diseases (e.g., sarcoidosis, tuberculosis) who are at heightened risk when receiving vitamin D supplementation. [1][2][3][5]
Vitamin D toxicity is rare and generally occurs only with daily intakes > 50,000 IU leading to serum 25‑(OH)D > 150 ng/mL; the recommended 5,000 IU daily regimen is well within the safe range. [6][7]8